An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

Published:2023-10-10 Issue:12 Volume:23 Page:1239-1244
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Simonetti Jacopo¹,Sgalla Giacomo²,Richeldi Luca¹²

Affiliation:

1. Unita Operativa Complessa di Pneumologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Università Cattolica del Sacro Cuore, Rome, Italy

2. Unita Operativa Complessa di Pneumologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione policlinico universitario “A. Gemelli” IRCCS, Rome, Italy

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2268014

Reference24 articles.

1. Idiopathic pulmonary fibrosis

2. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

3. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

4. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

5. Antibody-based therapies for idiopathic pulmonary fibrosis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis;Cells;2024-04-30

2. Comprehensive review of potential drugs with anti-pulmonary fibrosis properties;Biomedicine & Pharmacotherapy;2024-04